Research ArticleTheranostics
Open Access
FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Frederik L. Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn and Clemens Kratochwil
Journal of Nuclear Medicine February 2021, 62 (2) 201-207; DOI: https://doi.org/10.2967/jnumed.120.245084
Frederik L. Giesel
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Sebastian Adeberg
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
3Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
Mustafa Syed
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
Thomas Lindner
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Luis David Jiménez-Franco
6ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany
Eleni Mavriopoulou
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Fabian Staudinger
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Eric Tonndorf-Martini
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
Sebastian Regnery
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
Stefan Rieken
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
7Department of Radiation Oncology, University Hospital Göttingen, Göttingen, Germany; and
Rami El Shafie
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
Manuel Röhrich
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Paul Flechsig
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Andreas Kluge
6ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany
Annette Altmann
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Jürgen Debus
2Heidelberg Institute of Radiation Oncology, Heidelberg, Germany
3Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany
4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
5Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
Uwe Haberkorn
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
8Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
Clemens Kratochwil
1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Frederik L. Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil
Journal of Nuclear Medicine Feb 2021, 62 (2) 201-207; DOI: 10.2967/jnumed.120.245084
FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
Frederik L. Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil
Journal of Nuclear Medicine Feb 2021, 62 (2) 201-207; DOI: 10.2967/jnumed.120.245084
Jump to section
Related Articles
Cited By...
- 68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression
- Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT
- Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Biodistribution, Dosimetry, and Pharmacokinetics of 68Ga-CBP8: A Type I Collagen-Targeted PET Probe
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy